Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients

Abstract: Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals (≥60 years), who […]

Alternatives to Intensive Treatment in Patients With AML

Abstract: A significant proportion of patients with acute myeloid leukemia (AML) are unable to tolerate standard induction chemotherapy regimens. This is particularly true for patients who […]

Use of Venetoclax Combination Regimens in Chronic Lymphocytic Leukemia

H&O Is single-agent venetoclax a common treatment for chronic lymphocytic leukemia (CLL)? CT In CLL, venetoclax (Venclexta, AbbVie/Genentech) is typically not used as a single agent; […]

Mechanisms of Resistance to BTK Inhibitors in Patients With Chronic Lymphocytic Leukemia

H&O What are the mechanisms of action of ibrutinib and the next-generation Bruton’s tyrosine kinase (BTK) inhibitors? JW Ibrutinib and the second-generation covalent inhibitors acalabrutinib (Calquence, […]

Diagnosis and Management of Neutrophilic Myeloid Neoplasms

Abstract: Chronic neutrophilia is commonly seen with persistent infections, inflammatory disorders, smoking, solid tumors, and specific medications. However, after reactive causes have been excluded, a workup […]

FLT3 Inhibitors in Acute Myeloid Leukemia: Increasing Options

H&O What are the current treatments for acute myeloid leukemia (AML)? TK In the past 5 years, the US Food and Drug Administration (FDA) has approved […]

How I Manage Chronic Lymphocytic Leukemia

Introduction The therapeutic landscape for chronic lymphocytic leukemia (CLL) has changed dramatically in the last several years.1 The role of chemoimmunotherapy has declined, and we are […]

Asciminib for the Treatment of Patients With Chronic Myeloid Leukemia

H&O What is the current treatment approach for patients with chronic myeloid leukemia (CML)? JC Patients with CML begin treatment with a tyrosine kinase inhibitor (TKI) […]

The Evolving Use of Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

H&O What type of drug is gemtuzumab ozogamicin? RW Gemtuzumab ozogamicin (Mylotarg, Pfizer) is an antibody-drug conjugate that consists of a humanized anti-CD33 antibody attached to […]

Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia

H&O What are the outcomes associated with hypomethylating agents in acute myeloid leukemia (AML)? CD Decitabine and azacytidine, the hypomethylating agents typically used in this setting, […]

Choosing Between Novel Agents and Chemoimmunotherapy in CLL

H&O Which novel agents are available for physicians treating patients with chronic lymphocytic leukemia? JW Right now, we have Bruton tyrosine kinase (BTK) inhibitors, phosphoinositide-3 […]

Evolving Strategies for the Management of Core-Binding Factor Acute Myeloid Leukemia

H&O What are core-binding factors? GB Core-binding factors are heterodimeric transcription factors that are necessary at different stages of hematopoiesis. Core-binding factor alpha has 3 […]

Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia

Abstract: Measurable residual disease (MRD) quantification is an essential component of caring for patients with acute lymphoblastic leukemia (ALL). Many studies in pediatric and adult […]

Richter Transformation of Chronic Lymphocytic Leukemia in the Era of Novel Agents

Abstract: The increased use of several effective novel targeted therapy agents has revolutionized therapy for patients with chronic lymphocytic leukemia (CLL). Disease progression in patients […]

Assessing the Risk of Heart Failure in Patients With Acute Leukemia

H&O What is the risk of heart failure in patients with acute lymphoblastic leukemia or acute myeloid leukemia? MSC Heart failure in patients with acute […]

Treatment-Free Remission in Chronic Myeloid Leukemia

Abstract: Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed […]

Outpatient Administration of Liposomal Daunorubicin and Cytarabine (Vyxeos) in Patients With Secondary Acute Myeloid Leukemia

H&O What is secondary acute myeloid leukemia? MK The term secondary acute myeloid leukemia (AML) refers to 2 separate entities. One type derives from antecedent […]

New Drug Approvals in Acute Myeloid Leukemia: An Unprecedented Paradigm Shift

Abstract: We are witnessing an unprecedented paradigm shift in the treatment of acute myeloid leukemia (AML). For nearly 4 decades—since the introduction of cytarabine- and anthracycline-based […]

Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

H&O What is the mechanism of action for venetoclax, and why is it suited for chronic lymphocytic leukemia (CLL)? JS Venetoclax (Venclexta, AbbVie/Genentech) has a […]

Midostaurin for Patients With Acute Myeloid Leukemia and FLT3 Mutations

H&O What is the role of FLT3 in normal cells and acute myeloid leukemia? ML FLT3 is a receptor tyrosine kinase. The name stands for […]